Project Grant R44HL187038
Award Date 9/1/26
Completion Date 6/30/28
Dollars Obligated $1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77021, USA
Similar Awards
- Federal Project Grant Award Summary Vesteck, Inc. received a $1.36M Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded on September 15, 2025, with completion targeted for May 31, 2027. The award supports development and advancement of an endovascular suturing device designed to augment endograft fixation during endovascular repair (EVAR) of abdominal aortic aneurysms (AAA). The device addresses a...
- The National Heart, Lung, and Blood Institute awarded The Research Foundation For The State University of New York $740,447 on August 20, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to engineer self-healing, tissue-engineered vascular grafts for use as arteriovenous shunts in hemodialysis patients. The award funds development of self-healing tissue-engineered vessels (SH-TEVs) designed to withstand repeated needle cannulation while maintaining mechanical strength and...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded Anova Biomedical, Inc. $345,938 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop compliant and degradable peripheral vascular grafts for small-artery bypass procedures. Anova is refining fabrication techniques for NovaGraft, a vascular bypass graft made from a novel, fully degradable elastomer designed to match the mechanical properties of native arteries. The work...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Pavaj Vascular Corporation $1,094,070 on September 2, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop and advance nanoparticle-mediated drug delivery technology for preventing arteriovenous fistula stenosis in hemodialysis patients. Pavaj Vascular is engineering a therapy using poly(lactic-co-glycolic acid) nanoparticles encapsulated with calcitriol—the...
- The National Heart, Lung, and Blood Institute awarded Bridgesource Medical, Corp. $320,727 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a right heart catheter device that uses pressure-volume loop analysis to identify which patients with tricuspid regurgitation will benefit from percutaneous valve repair procedures. The device addresses a critical clinical gap in patient selection for tricuspid valve interventions. Approximately 1.5 million...
- The National Heart, Lung, and Blood Institute awarded Vantis Vascular Inc. (doing business as Crossliner Inc.) $496,437 on September 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to advance commercial readiness of a novel guide extension catheter for complex percutaneous coronary interventions. Vantis Vascular is developing a multi-functional guide extension catheter that combines deeper catheter intubation with a microcatheter leading tip and pre-dilatation...
- Venarum Medical LLC received a $255,619 Project Grant award from the National Science Foundation on August 15, 2021 to support research and development activities concluding on May 31, 2022. The funding was provided through the NSF's Engineering program (CFDA #47.041), which aims to improve quality of life and economic strength through engineering innovation and excellence. Specifically, the grant supports Venarum Medical's "SBIR PHASE I: INTEGRATED MANUFACTURING OF ARTIFICIAL VALVES FOR...
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University $577,334 on July 9, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a sensory airway stent for continuous monitoring of airway conditions. The recipient is creating a sensor-integrated airway stent (SAS) equipped with flexible sensors and a wearable magnetic actuation unit designed to monitor stent patency and airway health in the central airway. The innovation addresses central airway...
- The National Heart, Lung, and Blood Institute awarded Fastline LLC $306,383 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and test a second-generation one-handed central venous line (CVL) placement device. Fastline is engineering a simplified CVL insertion device that enables operators to perform all steps of central vein access—needle puncture, aspiration/injection, manometry testing, and guidewire placement—with a single hand while...
- The National Heart, Lung, and Blood Institute awarded MDC Studio, Inc. $309,813 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop an automated vascular access device that enables less-experienced providers to safely and reliably perform central venous and arterial cannulation. The R61 phase focuses on automating the core steps of successful cannulation. MDC Studio will design, construct, and test sensors and automation to detect blood vessel...